|Bid||0.00 x 100000|
|Ask||0.00 x 100000|
|Day's Range||20.11 - 20.82|
|52 Week Range||9.45 - 23.17|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It’s take two for Sprout Pharmaceuticals and Addyi, the only drug approved by the U.S. Food and Drug Administration to treat low sexual desire disorder (HSDD) in women.
Valeant Pharmaceuticals (VRX) is one of the pharmaceutical companies that’s focused on developing and commercializing prescription pharmaceuticals, generic pharmaceuticals, over-the-counter products, and eye care products. Wall Street analysts expect revenues of ~$2.1 billion during the second quarter.
Pour consulter la lettre d'information; cliquez sur le lien: http://share.thomsonreuters.com/assets/newsletters/Morning_News_Call/MNCCA_FR_05082018.pdf PRINCIPAUX INDICATEURS À L’AGENDA 08:15 Mises en ...
From a headline standpoint, Allergan plc (NYSE:AGN) stock does look attractive at the moment. A steady pullback has seen Allergan stock fall about 35% from late July highs and Allergan has dropped by half from 2015 levels. A sub-10x forward EPS multiple is notably cheaper than those assigned to rivals like Pfizer Inc. (NYSE:PFE) and Merck & Co., Inc. (NYSE:MRK).
For investors, biotech stocks remain one of the most dynamic sectors out there. On one hand, you have some of the largest pharmaceutical firms on the planet with multi-billion-dollar blockbuster drugs filling their coffers. On the other, you have the more stereotypical “lotto ticket” biotech stocks of clinical or early production stage firms.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) still has its share of detractors. Late last month Valeant stock came out with its quarterly confessional, which featured an improving and profitable bottom-line of 98-cents-per-share.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock took a hit today following the release of its earnings report for the fourth quarter of 2017. The big blow to VRX stock today was the company’s revenue of $2.16 billion for the fourth quarter of the year. It also came in below Wall Street’s revenue estimate of $2.18 billion for the quarter.
It shows revenues of $222.8 million, nearly double the previous year’s $130 million, and a gross profit of $121 million. During my reporting career, I have seen several Canadian companies rise, and then fall, on their own hype.
Pour consulter la lettre d'information; cliquez sur le lien: http://share.thomsonreuters.com/assets/newsletters/Morning_News_Call/MNCCA_FR_08082017.pdf PRINCIPAUX INDICATEURS À L’AGENDA Pas d’indicateurs ...